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Abstract 
Review on INPP4B, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
Inositol Polyphosphate-4-Phosphate Type II B 
(INPP4B), tumor suppressor, PI3K/AKT pathway 
Identity 
HGNC (Hugo) 
INPP4B 
Location 
4q31.21; Start: 142,023,160 bp End: 142,847,432 
bp; 824.273 bases; Orientation: Minus strand 
Local order 
From centromere to telomere: LINC02276, IL15, 
INPP4B, LOC07986194, LOC100287014. 
Local order of INPP4B. Local order is shown together with leading and subsequent genes on chromosome 4. The 
direction of arrows indicates transcriptional directions on the chromosome and arrow sizes approximate gene 
sizes. 
DNA/RNA 
Note 
Human INPP4B gene is about 824 kb, localized at 
4q31.1 and minus oriented. There are 27 exons of 
human INPP4B; the first four exons and a part of 
exon 5 form 5' untranslated region (UTR). A huge 
part of exon 27 constitutes 3' UTR (Croft et al., 
2017). Mouse Inpp4b consists of 25 exons with the 
size of 45 to 1340 nucleotides. Two of those exons 
are 5' untranslated. The entire mouse Inpp4b gene is 
600 kb. Gene locus is remarkably conserved between 
human and mouse (Ferron and Vacher, 2006). 
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Numbers and illustrative sizes of exons of human INPP4B. Red boxes are the coding region and black boxes are 
the non-coding ones. Data adapted from Croft et al., 2017. 
Transcription 
In murine studies, an alternative-spliced form of 
cDNA, which was called Inpp4bαs and did not 
include exon 5 compared to Inpp4bα, was identified 
(Ferron and Vacher, 2006). 
There are three identified transcript variants of 
human INPP4B. Variant 1 has 27 exons; variant 2 
and 3 have 26. Transcript variant 1 of human 
INPP4B is 4.590 bp; variant 2 is 8.984 bp and variant 
3 is 9.083 bp (NCBI, NM_001331040.1; 
NM_001101669.2; NM_003866.3). Variant 1 and 2 
encode the same isoform but their 5' untranslated 
region (UTR) differ from each other. Variant 3 
contains an alternative 3' coding region and a novel 
3' UTR compared to variant 1 (NCBI, 2017). 
Recently, Croft et al. isolated a novel variant of 
INPP4B, called INNP4B-S. This variant was shown 
to include an extra 27 bp from the sequence between 
exon 15 and 16, called exon 15A. Also, exons 20-24 
were illustrated to be spliced compared to previous 
variants (Croft et al., 2017). ). 
In murine studies, transcription start site of Inpp4b 
was shown to be tissue specific (Ferron and Vacher, 
2006). In human colon cancer cell lines, ETS1 was 
shown to regulate the expression of INPP4B by 
directly binding to promoter region of the gene (Guo 
et al., 2016). 
Protein 
Note 
There are two isoforms of INPP4B protein, called 
INPP4Bα and INPP4Bβ (Billclif and Lowe, 2014). 
Mouse Inpp4bα cDNA encodes a 927 amino acid 
protein while Inpp4bβ cDNA encodes a 941 amino 
acid protein with a molecular weight of ~105 kDa 
which is the same with that of human INPP4B 
protein (Uniprot: O15327). INPP4B consists of an 
N-terminal C2-lipid binding domain, Nervy 
Homology 2 (NHR2) domain and a C-terminal dual 
phosphatase domain including a conserved 
Cys(X)5Arg motif. NHR2 is responsible for 
oligomerization and protein-protein interaction 
(Agoulnik et al., 2011). 
 
Illustration of INPP4B protein. INPP4B protein consists of C2-lipid binding domain, Nervy Homology 2 
(NHR2) domain and C-terminal dual phosphatase domain where conserved Cys(X)5Arg motif locates. Data 
adapted from Agoulnik et al., 2011. 
Expression 
Inpp4bα has a broad tissue expression with higher 
levels in brain, skeletal muscle, lung, spleen, testis  
 
and thymus. Nevertheless, Inpp4bβ has a limited 
expression in brain, small intestine, skeletal muscle 
and heart (Ferron and Vacher, 2006). 
 
Expression profile of INPP4B in the tissues. INPP4B is moderately expressed in a numerous tissues including 
brain, muscles, pancreas, intestines, kidney, testis, prostate, breast and endometrium. Data taken from The 
Human Protein Atlas (http://www.proteinatlas.org) in April, 2017. 
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Localisation 
Alpha form of INPP4B and INPP4B-S localize in 
cytoplasm while beta form mainly localize in Golgi 
apparatus (Ferron and Vacher, 2006; Billcliff and 
Lowe, 2014; Croft et al., 2017). 
Function 
Inositol polyphosphate 4-phosphate type II 
(INPP4B) is an enzyme responsible for 
phosphoinositide homeostasis. The major substrate  
 
for INPP4B is phophatidylinositol 3,4-biphosphate 
(PI(3,4)P2). PI(3,4)P2 is dephospharylated by 
INPP4B on D4 position and converted to 
phophatidylinositol 3-phosphate (PI(3)P). Those are 
critical secondary messengers in cells. Also, the 
substrate of INPP4B, PI(3,4)P2 is necessary for the 
activation of AKT. Thus, INPP4B is a negative 
regulator of PI3K/AKT signaling pathway. AKT is a 
potent driver of tumorigenic cell growth. Hence, 
INPP4B was at first proposed as a tumor suppressor 
protein. However, INPP4B was illustrated to activate 
serum glucocorticoid-regulated kinase 3 ( SGK3), 
which also promotes cellular proliferation and 
growth, via production of PI(3)P and in turn could be 
oncogenic (Chi et al., 2015; Guo et al., 2016). 
INPP4B was also demonstrated to have a role in 
nerve conduction velocity (Lemcke et al., 2014) and 
regulation of osteoclast differentiation (Ferron et al., 
2011; Vacher, 2013). Moreover, INPP4B was shown 
to dephosphorylate phosphotyrosine analogs, 
paranitrophenyl phosphate (pNPP) and 6,8-difluoro-
4-methylumbelliferyl (DifMUP), pointing that 
INPP4B has a protein tyrosine phosphatase activity 
(Lopez et al., 2013). 
 
Functions of INPP4B protein. INPP4B dephosphorylates PI(3,4)P2 to PI(3)P. PI(3,4)P2 is a secondary messenger 
which is important for activation of AKT to promote cell proliferation, survival, migration and invasion. Thus, 
INPP4B proposed as a tumor suppressor. However, the product of INPP4B, PI(3)P was shown to trigger 
activation of SGK3 which also promotes those phenotypes. So, INPP4B was further proved to be oncogenic. 
Besides, INPP4B is fundamental for the regulation of nerve conduction velocity and osteoclast differentiation. 
Data adapted from Chew et al., 2015b. 
Homology 
Human and mouse INPP4B proteins share 96% 
identity. All mammalian INPP4B proteins include a 
Cys(X)5Arg phosphatase catalytic site and a 
conserved C2 domain (Ferron and Vacher, 2006). C2 
lipid binding domain of INPP4B is 91% identical 
between human and mouse (Agoulnik et al., 2011). 
Mutations 
The C-terminal lipid phosphatase domain contains C 
842KSAKDRT (aa 842-849) motif which is 
conserved between type I and II phosphatases. 
Mutation of cysteine at position 842 to alanine in this 
motif causes INPP4B to unable to dephosphorylate 
phosphatidylinositols (Agoulnik et al., 2011). Also, 
K846M mutation resulted in loss of lipid 
phosphatase activity without affecting protein 
phosphatase activity and D847E mutation caused to 
loss of protein phosphatase activity and decrease in 
lipid phosphatase activity (Lopez et al., 2013). In a 
case study where samples from patients with gastric 
cancer (GC) and colorectal cancer (CRC) were used, 
an A7 repeat at the 25th exon of INPP4B was 
analyzed. An identical frameshift mutation, through 
deletion of one base, in the A7 repeat region was 
identified in two CRCs (2/79: 2.5%) and one GC 
(1/34: 2.9%) patient (Choi et al., 2016). 
Implicated in 
 
When firstly identified, INPP4B was proposed as a 
tumor suppressor especially when PTEN was 
deficient (Gewinner et al., 2009; Kofuji et al., 2015; 
Vo and Fruman, 2015); however, some studies proved 
that it could promote carcinogenesis. 
Melanoma 
Chi et al. showed that INPP4B is upregulated in 
melanoma cell lines and human tissues. Even though 
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INPP4B was shown to negatively regulate 
PI3K/AKT signaling and thus, it was thought to be 
tumor suppressor, INPP4B was demonstrated to be 
an oncogenic driver through activation of serum 
glucocorticoid-regulated kinase 3 (SGK3) and 
independently of AKT. INPP4B downregulation 
inhibited cell proliferation and tumor growth in 
xenograft while its overexpression caused enhanced 
cell proliferation and anchorage-independent growth 
of melanocytes (Chi et al., 2015). On the other hand, 
INPP4B expression was inversely correlated with 
tumor progression in melanocytic neoplasms (Perez-
Lorenzo et al., 2014). 
Colon Cancer 
INPP4B was demonstrated to be oncogenic and 
upregulated in human colon cancer cells and tissue. 
Silencing of INPP4B blocked the activation of AKT 
and SGK3, and inhibited cell proliferation and tumor 
growth in xenograft. Overexpression of INPP4B 
resulted in anchorage-independent growth of normal 
colon epithelial cells. Also, INPP4B was illustrated 
to dephosphorylate PTEN in colon cancer cells (Guo 
et al., 2016). 
Thyroid Cancer 
Chew et al. showed loss of Innp4b in Pten 
heterozygous mice leaded to follicular thyroid 
carcinoma. INPP4B was also demonstrated to inhibit 
PI3K-C2 Endometrial Cancer α-mediated AKT2 
activation in early endosomes in thyroid cancer cells 
(Chew et al., 2015). INPP4B was downregulated in 
human thyroid cancer cell lines and samples (Chew 
et al., 2015; Kofuji et al., 2015). 
Endometrial Cancer 
INPP4B was demonstrated to be downregulated in 
samples from patients with endometrial cancer 
(Kofuji et al., 2015). 
Prostate Cancer 
Hodgson et al. showed that activation of androgen 
receptor induced the expression of INPP4B via 
activation of corepressor, NCOR1, which regulates 
agonist-bound androgen receptor activity, and 
decreased the activation of AKT in prostate cancer 
cell lines. Also, INPP4B expression was shown to be 
down-regulated in samples from androgen-
dependent prostate cancer (Hodgson et al., 2011). 
Same group also showed that de novo expression of 
INPP4B suppressed the invasion in vitro and in vivo 
in human prostate carcinoma cells due to that 
INPP4B regulated a wide range of genes associated 
with cell adhesion, extracellular matrix and 
cytoskeleton. It also inhibited metastases thanks to 
downregulating metastases-related BIRC5, 
phosphorylated PKC, expression of PKC in 
androgen-dependent and -independent manner and 
PTGS2 (COX-2). Moreover, de novo expressed 
INPP4B inhibited proinflammatory cytokine 
CXCL8 (IL-8) and induced PAK6  owing to 
downregulating PKC (Hodgson et al., 2014). In 
another study, overexpression of INPP4B in prostate 
cancer cell line, PC3, inhibited cell proliferation and 
decreased the levels of phosphorylated AKT (p-
AKT), bringing about G1 arrest. Combination of 
INPP4B overexpression with PARP inhibitor, which 
arrested the cells in G2/M with an increase in p-AKT 
level, decreased the p-AKT levels and further 
inhibited the cell proliferation, suggesting that those 
combinations could be helpful for treatment of 
prostate cancer (Ding et al., 2014). INPP4B was also 
demonstrated to associate with the resistance to 
chemotherapeutics in prostate cancer. In docetaxel-
resistant prostate cancer cell lines, INPP4B was 
shown to be downregulated. Overexpression of 
INPP4B resensitized the resistant cell lines towards 
docetaxel via inhibiting PI3K/AKT activation and 
expression of the mesenchymal markers fibronectin, 
N-cadherin, and vimentin, and upregulating the 
expression level of the epithelial maker E-cadherin 
(Chen et al., 2016). 
Breast Cancer 
INPP4B was shown to be expressed in non-
proliferative estrogen receptor (ER)-positive cells in 
normal breast tissue and ER-positive breast cancer 
cell lines. Nevertheless, ER-negative breast cancer 
cell lines did not express INPP4B. As a 
generalization, INPP4B expression was not seen in 
phosphatase and tensin homolog (PTEN)-null 
tumors. Down-regulation of INPP4B in ER-positive 
breast cancer cell lines increased AKT activation, 
cell proliferation and xenograft tumor growth while 
overexpression of INPP4B in ER-negative cell lines 
decreased the activated AKT and anchorage-
independent growth (Fedele et al., 2010). Similarly, 
in triple negative breast cancer cell line, MDA-MB-
231, stably overexpression of INPP4B inhibited cell 
proliferation and arrested the cell cycle at G1 phase 
through decreasing the level of phosphorylated 
AKT. By the combinational therapy approach, 
INPP4B expression was shown to increase the 
efficacy of poly-(adenosine diphosphate ribose) 
polymerase (PARP) inhibitor, AG014699 which is a 
DNA-damaging agent, arresting cell cycle at G2/M 
transition but could activate PI3K/AKT pathway 
(Sun et al., 2014). In a review article, Bertucci and 
Mitchell reported that INPP4B expression was lost 
in 84% of basal-like breast cancer; INPP4B loss of 
heterozygosity (LOH) occurs in 55% of triple 
negative and basal-like cancers, and 60% of BRCA1 
mutant tumors as previously shown by Gewinner et 
al. (Gewinner et al., 2009; Bertucci and Mitchell, 
2013). Similarly, INPP4B LOH was observed in 
18.1% of Japanese breast cancer patients. Moreover, 
INPP4B LOH was significantly correlated with 
estrogen receptor (ER) and progesterone receptor 
(PR) negativity, higher nuclear grade, PTEN LOH 
and poorer prognosis (Tokunaga et al., 2016). In a 
case study where breast cancer samples from 43 
patients were used, INPP4B expression was absent 
or low for 18% of cases. Low expression INPP4B 
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was associated with larger tumor size and higher 
nuclear grade (Sueta et al., 2014). In another study, 
INPP4B was shown to prevent AKT activation but 
trigger the activation of SGK3, which was 
overexpressed and hyperactivated in breast cancer 
and caused to proliferation, invasive migration and 
tumorigenesis in breast cancer in vitro and in vivo 
models, via production of PI(3)P (Gasser et al., 
2014). 
Acute Myeloid Leukemia (AML) 
Dzneladze et al. showed that high levels of INPP4B 
in AML patients had poor response to induction 
therapy, shorter event-free survival and shorter 
overall survival. In cell culture, overexpression of 
INPP4B increased the colony formation potential, 
resulted in resistance to daunorubicin and ionizing 
radiation and supported phosphatase-dependent and 
AKT-independent proliferation. Hence, the 
researchers proposed INPP4B as an independent 
prognostic marker in AML (Dzneladze et al., 2015). 
Similarly, INPP4B was shown to be overexpressed 
in samples from patients with AML in another study. 
Overexpression of INPP4B in patients with AML 
resulted in reduced response to chemotherapy, early 
relapse and poor overall survival as figured out by 
Dzneladze et al. Moreover, overexpression of an 
inert variant of INPP4B, which did not display 
phosphatase activity, did not affect the resistance 
phenotype in vitro. However, silencing of INPP4B 
sensitized the AML cell lines towards 
chemotherapeutics, pointing a phosphoinositide 
phosphatase function-independent involvement of 
INPP4B in drug resistance in AML (Rijal et al., 
2015). 
Laryngeal Cancer 
In laryngeal cancer cell line, HEp-2, INPP4B 
expression was triggered by hypoxia and irradiation. 
Also, INPP4B overexpression enhanced aerobic 
glycolysis. It was demonstrated that one of the 
glycolysis-regulatory gene, hexokinase-2 (HK2) was 
regulated by INPP4B via AKT-mTOR pathway in 
this cell line. Silencing of both INPP4B and HK2 
sensitized the radioresistant cells toward radiation 
and chemotherapeutic agents (Min et al., 2013). 
Moreover, INPP4B was demonstrated to be a marker 
of radioresistance in HEp-2 cells. INPP4B was 
shown to be overexpressed in radioresistant HEp-2 
cells and that radiation or anticancer drug treatment 
induced INPP4B expression which was blocked by 
inhibition of extracellular signal-regulated kinase 
(ERK). INPP4B overexpression increased the 
resistance towards radiation and anticancer drugs 
and depletion of INPP4B re-sensitized the cells (Kim 
et al., 2012). 
Nasopharyngeal Carcinoma (NPC) 
NPC is a viral-associated neoplasm where Epstein-
Bar virus latent proteins affect multiple signaling 
cascades. Yuen et al. showed that INPP4B was 
downregulated in NPC cell lines compared to normal 
nasopharyngeal epithelial cell lines. The 
downregulation was demonstrated to become as a 
result of hypermethylation of the 5'CpG island of 
INPP4B (Yuen et al., 2014). 
Lung Cancer 
In a case study where samples were obtained from 
180 patients with non-small cell lung cancer 
subtypes, squamous cell carcinoma (SSC) or 
adenocarcinoma (ADCA), the ratio of INPP4B copy 
number was determined as 15% ≤1 copies, 62% 2 
copies, and 23% ≥3 copies. Also, 47% displayed loss 
of loss of INPP4B expression which showed a strong 
correlation with SCC compared to ADCA 
(Stjernstrom et al., 2014). In another study, MIR937 
which targeted INPP4B by directly binding to 3 UTR 
of INPP4B was upregulated in lung cancer cell line. 
Overexpression of miR-937 promoted anchorage-
dependent and -independent growth while 
downregulation prevented these effects. 
Overexpression of miR-937 was shown to 
knockdown INPP4B which was proposed as the 
reason for increased growth rate in lung cancer cell 
lines (Zhang et al., 2016). 
Bladder Cancer 
Hsu et al. developed ESR1 (estrogen receptor-α, 
ERα)--knockout mice to see the effect of ERα in 
bladder carcinogenesis. They showed that ERα 
reduced the carcinogen-induced malignant 
transformation ability. Moreover, ESR1 was 
demonstrated to control AKT activity via controlling 
the expression of INPP4B (Hsu et al., 2014). 
Ovarian Cancer; Ovarian Teratomas 
(OTs) in particular 
Teratoma is a class of tumors that are composed of 
ecto-, meso- and endodermal tissues which are all 
foreign to the site of the origin. OTs are 
pathogenically activated non-ovulated germ cells-
derived ovary tumors that exhibit disorganized 
pattern of cellular differentiation. Carriers of Rous 
sarcoma virus (RSV) Tgkd transgene are susceptible 
to teratomas. Tgkd transgene was demonstrated to be 
inserted into intergenic region of Inpp4b and Il15. 
This insertion was shown to affect Inpp4b 
expression and dysregulation of Akt pathway, 
promoting progression of ovarian teratomas 
(Balakrishnan and Chaillet, 2013). In ovarian cancer 
cells, INPP4B was illustrated to form a complex with 
BRCA1  and ATR which are the members of DNA 
repair mechanism. Loss of INPP4B, which was seen 
in 40% of patients with ovarian cancer studied, 
disrupted in BRCA1, ATM  and ATR protein 
stabilities, resulting in DNA defects and sensitized 
the cells towards inhibitors of PARP, a nuclear 
enzyme sensing DNA single strand breaks and 
required for base excision repair (Ip et al., 2014). 
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Hepatocellular Carcinoma 
In hepatocellular carcinoma cell lines, MIR765  
which directly targeted INPP4B was shown to be 
upregulated. Upregulation of miR-765 and in turn 
downregulation of INPP4B increased upregulation 
of p-AKT, CCND1 (Cyclin D1), and downregulation 
of p- FOXO3, p21 expression; thus it increased 
cellular proliferation and tumorigenicity. 
Downregulation of miR-765 rescued the phenotype 
in these cell lines via upregulation of INPP4B (Xie 
et al., 2016). 
Osteoporosis 
Osteoporosis is a genetic disease where bone mass is 
reduced because of dysregulation of osteoclast 
differentiation and maturation. Ferron et al. proposed 
Inpp4bα as a regulator of osteoclastogenesis. 
Inpp4bα was detected to be expressed from early 
osteoclast differentiation to activation. Moreover, 
phosphotase-inactivate Inpp4bα triggered the 
osteoclast activation. Inpp4bα was shown to control 
intracellular calcium level modulating NFATC1, 
which is a preosteoclast promoting transcription 
factor regulating osteoclast maturation, nuclear 
translocation and activation. Inpp4b-deficient mice 
displayed increased osteoclast differentiation rate, 
bringing about decreased bone mass and 
osteoporosis, and human INPP4B was proposed as a 
susceptibility locus for osteoporosis. Overall, 
Inpp4bα was regarded as a negative regulator of 
osteoclast differentiation (Ferron et al., 2011; 
Vacher, 2013). 
Multiple Sclerosis (MS) 
MS is a neurodegenerative and neuroinflammatory 
disease causing impairment of nerve conduction. In 
a genomic study, INPP4B was shown to regulate 
nerve conduction velocity. Moreover, an INPP4B 
polymorphism (rs13102150) was associated with 
MS cohorts (Lemcke et al., 2014). 
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